Midatech Pharma PLC Proclaims Results of Common Assembly

Results of Common Assembly

Appointment of Specialist Enterprise Advisory Agency – Quantuma

ABINGDON, OXFORDSHIRE / ACCESSWIRE / January 23, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug supply know-how firm centered on bettering the bio-delivery and biodistribution of medicines, broadcasts that at its Common Assembly held at 10.00 a.m. in the present day all atypical resolutions had been carried, however all different resolutions weren’t handed by shareholders, as set out within the desk under. As sure resolutions had been inter-conditional, solely Decision 4 (common authority to allot securities) was due to this fact handed. Accordingly, the proposed acquisition of Bioasis Applied sciences, Inc. and the proposed transactions associated thereto, together with the Change of Identify, won’t proceed.

Whereas the Firm has enough money sources to fund its operations till mid-March 2023 and the Board will search to protect its money sources so far as practicable, it urgently requires a dedication for different sources of funding prematurely of mid-March 2023 to have the ability to proceed as a going concern and the Board are exploring choices. There will be no assure that the Firm will have the ability to discover different sources of funding on a well timed foundation. If different funding will not be accessible, the Administrators imagine that it’s probably that the Firm may very well be compelled to enter into administration.

The Board needs to make sure that it’s performing in the most effective pursuits of collectors and different stakeholders. Due to this fact, in mild of in the present day’s vote on the Common Assembly and its monetary place, the Firm has appointed Quantuma Advisory Restricted, a specialist enterprise advisory agency, to undertake contingency planning and supply recommendation to the Board of Administrators on applicable actions.

Additional announcement(s) might be made as and when applicable.

Capitalised phrases shall have the identical meanings as these set out within the Firm’s round dated 5 January 2023.

The votes acquired in respect of the Resolutions had been as follows:





That the administrators be authorised to allot the Transaction Shares






That the administrators be authorised to allot shares in reference to the difficulty of the New Choices, the New Warrants and the Bioasis Warrants






That the administrators be authorised to allot the Cresence Shares






That the administrators be typically authorised to allot shares






That the administrators be authorised to disapply the statutory pre-emption provisions in reference to the authorisation to allot shares






That the administrators be authorised to disapply the statutory pre-emption provisions in reference to the authorisation to allot shares






That the administrators be authorised to disapply the statutory pre-emption provisions in reference to the authorisation to allot shares






That the administrators be authorised to disapply the statutory pre-emption provisions in reference to the authorisation to allot shares






That Midatech Pharma Plc modifications its title to Biodexa Prescribed drugs PLC





The overall variety of votes solid represented roughly 35.6% of the Firm’s complete issued share capital.

This announcement comprises inside info for the needs of Article 7 of the Market Abuse Regulation (EU) 596/2014, because it types a part of UK home regulation by advantage of the European Union (Withdrawal) Act 2018, as amended.

For extra info, please contact:

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)29 20480 180


Strand Hanson Restricted (Nominated Adviser)

James Dance / Matthew Chandler / Rob Patrick

Tel: +44 (0)20 7409 3494

Turner Pope Investments (TPI) Ltd (Joint Dealer)

Andrew Thacker / James Pope

Tel: +44 (0)20 3657 0050

IFC Advisory Restricted (Monetary PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

E-mail: [email protected]

Edison Group (US Investor Relations)

Alyssa Issue

Tel: +1 (860) 573 9637

E-mail: [email protected]

About Midatech Pharma PLC

Midatech Pharma PLC (twin listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug supply know-how firm centered on bettering the bio-delivery and bio-distribution of medicines. The Firm combines authorised and growth medicines with its proprietary and progressive drug supply applied sciences, to offer compelling merchandise which have the potential to powerfully affect the lives of sufferers.

The Firm has developed three in-house know-how platforms, every with its personal distinctive mechanism to enhance supply of medicines to websites of illness. The entire Firm’s applied sciences have efficiently entered human use within the clinic, offering necessary validation of the potential for every platform:

  • Q-Sphera™ platform: a disruptive micro-technology used for sustained launch to delay and management the discharge of therapeutics over an prolonged time frame (from weeks to months).

  • MidaSolve™ platform: an progressive nanotechnology used to dissolve insoluble medication in order that they are often administered in liquid kind instantly and domestically into tumours.

  • MidaCore™ platform: a modern nanotechnology used for focusing on medicines to websites of illness.

The platform nature of the applied sciences affords the potential to develop a number of drug belongings relatively than being reliant on a restricted variety of programmes. Midatech’s applied sciences are supported by 36 patent households together with 120 granted patents and a further 70 patent purposes. Midatech’s headquarters and R&D facility is in Cardiff, UK. For extra info please go to www.midatechpharma.com

Ahead-Wanting Statements

Sure statements on this announcement might represent “forward-looking statements” throughout the that means of laws in the UK and/or the USA Non-public Securities Litigation Reform Act. All statements contained on this announcement that don’t relate to issues of historic truth ought to be thought of forward-looking statements.

In sure circumstances, forward-looking statements will be recognized by way of phrases akin to “plans”, “expects” or “doesn’t anticipate”, or “believes”, or variations of such phrases and phrases or statements that sure actions, occasions or outcomes “might”, “may”, “would”, “may” or “might be taken”, “happen” or “be achieved”. Ahead-looking statements and knowledge are topic to varied recognized and unknown dangers and uncertainties, lots of that are past the flexibility of Midatech to regulate or predict, which will trigger their precise outcomes, efficiency or achievements to be materially completely different from these expressed or implied thereby, and are developed primarily based on assumptions about such dangers, uncertainties and different elements set out herein.

Reference ought to be made to these paperwork that Midatech shall file now and again or bulletins which may be made by Midatech in accordance with the London Inventory Change’s AIM Guidelines for Firms (“AIM Guidelines”), the Disclosure and Transparency Guidelines (“DTRs”) and the foundations and rules promulgated by the US Securities and Change Fee, which comprises and identifies different necessary elements that would trigger precise outcomes to vary materially from these contained in any projections or forward-looking statements. These forward-looking statements converse solely as of the date of this announcement. All subsequent written and oral forward-looking statements by or regarding Midatech are expressly certified of their entirety by the cautionary statements above. Besides as could also be required underneath the AIM Guidelines or the DTRs or by related regulation in the UK or the USA, Midatech doesn’t undertake any obligation to publicly replace or revise any forward-looking statements due to new info, future occasions or in any other case arising.

This info is offered by RNS, the information service of the London Inventory Change. RNS is authorised by the Monetary Conduct Authority to behave as a Main Info Supplier in the UK. Phrases and circumstances referring to the use and distribution of this info might apply. For additional info, please contact [email protected] or go to www.rns.com.

SOURCE: Midatech Pharma PLC

View supply model on accesswire.com:

Previous post Mike McCarthy defends controversial punt
Next post Jessica Simpson posts household selfie and ‘touching’ tribute for her mother